GCP
CLPT icon

GSA Capital Partners’s ClearPoint Neuro CLPT Stock Holding History

GSA Capital Partners’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,583
Closed -$292K – 1786
2025
Q1 		$292K Sell
24,583
-1,250
-5% -$19.4K 0.03% 1174
2024
Q4 		$397K Buy
+25,833
New +$335K 0.03% 1045

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

GSA Capital Partners's CLPT Position: Q2 2025 in Review

GSA Capital Partners sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 24,583 shares — an estimated $292K sold.

GSA Capital Partners first reported a position in CLPT in Q4 2024 and held it in 2 quarters. The position peaked at $397K in Q4 2024. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

  • GSA Capital Partners reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 24,583 ClearPoint Neuro shares in Q2 2025, an estimated $292K.
  • GSA Capital Partners first reported a position in ClearPoint Neuro in Q4 2024 and held it in 2 quarters.
  • GSA Capital Partners's ClearPoint Neuro position peaked at $397K in Q4 2024.
  • 96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.